Zusammenfassung Moderna Earnings $MRNA (-3,36 %)

$MRNA | Moderna Q2'24 Earnings Highlights:

🔹 EPS: -$3.33 (Est. -$3.35) 🟢

🔹 Revenue: $241M (Est. $128.41M) 🟢; -30% YoY

🔸 Spikevax (COVID-19 Vaccine) Sales: $184M; DOWN -37% YoY

Cuts Guidance:

🔹 FY'24 Revenue: $3-3.5B (Est. $3.83B) 🔴

CEO Stéphane Bancel's Commentary:

🔸 "During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs. We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S."

Challenges:

🔸 EU Sales: Very low expected sales due to budget constraints and competitive pressure

🔸 Competitive Environment: Increased competition in the COVID and RSV vaccine markets

🔸 Revenue Deferrals: Potential deferrals for some international COVID sales into 2025

Financial Framework for FY'24:

🔸 Net Product Sales: $3-3.5B

🔸 Cost of Sales: 40-50% of product sales

🔸 R&D Expenses: ~$4.5B

🔸 SG&A Expenses: ~$1.3B

🔸 Capital Expenditures: ~$0.9B

🔸 Year-End Cash and Investments: ~$9B

Key Developments:

🔸 RSV Vaccine (mRESVIA) Approval: Received FDA approval and began U.S. deliveries in July

🔸 Next-Gen COVID-19 Vaccine: Positive Phase 3 data for mRNA-1283

🔸 Seasonal Flu + COVID Vaccine: Positive Phase 3 data for mRNA-1083

Business Outlook:

🔸 COVID-19 and RSV Vaccines: Targeting increased market share in the U.S. and EU, but facing significant competitive pressure

🔸 Pipeline Progress: Continued development of next-gen vaccines and individualized therapies